Results 201 to 210 of about 25,158 (238)

Astrocyte CB ₁ receptors drive blood-brain barrier disruption in CNS inflammatory disease

Colomer T, Sánchez-Martín E, Bernal-Chico A, Moreno-García A, Serrat R, Baraibar A, Uribe-Irusta A, Iriarte-Sarria A, Skupio U, Matute C, Tepavcevic V, Fernández-Moncada I, Chapouly C, Marsicano G, Mato S.   +14 more
europepmc   +1 more source

Dynamic mechanism for subtype selectivity of endocannabinoids. [PDF]

J Biol Chem
Dutta S, Zhao L, Shukla D.
europepmc   +1 more source

Receptor-Selective Modulation of Cannabinoid Signaling by Cardamonin: Integrating Molecular Dynamics, Free Energy Calculations, and Behavioral Validation. [PDF]

ACS Omega
Khalid MH, Azmi L, Mubarak MQE, Iqma Marsujak NM, Syahir A, Perimal EK, Sulaiman MR, Mohamad Jamali MA.   +7 more
europepmc   +1 more source

The Endocannabinoid System in Neuropsychiatric Disorders: Mechanisms, Dysregulation and Therapeutic Potential. [PDF]

Biomedicines
Mušić T, Turnšek TL.
europepmc   +1 more source

Cannabinoids in Motor Control: From Receptor Distribution to Motor Disorders. [PDF]

Biomedicines
Faganeli D, Lipnik-Stangelj M.
europepmc   +1 more source

Reduced CB1 Cannabinoid Receptor Expression in Alzheimer's Disease and Transgenic Mouse Models. [PDF]

Aging Med (Milton)
von Borcke N, Purwien AV, Steiert A, Hasecke H, Bouter Y.   +4 more
europepmc   +1 more source

The role of CB1 receptors in psychostimulant addiction

Addiction Biology, 2008
ABSTRACTRecent studies have implicated the endocannabinoid (eCB) system in the neuronal mechanisms underlying substance dependence. Here, we review results of studies using cannabinoid receptor subtype 1 (CB1) knockout mice as well as CB1 antagonists to elucidate the role of this neurotransmitter system in psychostimulant addiction. The overall picture
Wiskerke, J., Pattij, T., Schoffelmeer, A.N.M., de Vries, T.J.   +3 more
openaire   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

The Cannabinoid CB1 Receptor in Schizophrenia

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021
Converging lines of evidence from epidemiological, preclinical, and experimental studies indicate that the endocannabinoid system may be involved in the pathophysiology of schizophrenia and suggest that the cannabinoid CB1 receptor may be a potential therapeutic target.
Faith Borgan, Michelle Kokkinou, Oliver Howes   +2 more
openaire   +3 more sources

Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex

Neurochemistry International, 2010
The cannabinoid CB1 receptor has gained much attention as a potential pharmacotherapeutic target in various neurodegenerative diseases including Alzheimer's disease (AD).
Jasinda H Lee, Jonathan H Williams, Gordon K Wilcock   +2 more
exaly   +2 more sources